-

Palleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney Week

– Presentation will provide an update on HLX79/E-602, a first-in-class human sialidase enzyme therapeutic, in patients with membranous nephropathy –

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver a late-breaking oral presentation at the 2026 American Society of Nephrology (ASN) Kidney Week, taking place October 21-25 in Denver, Colorado. Palleon’s presentation will take place on Friday, October 23.

Details of Palleon’s Presentation:

American Society of Nephrology (ASN) Kidney Week

Title: HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy
Oral Presentation Date and Time: Friday, October 23 from 11:00 to 11:15 AM MDT, Bluebird Ballroom; presented by Brad Rovin, M.D., Director, Division of Nephrology at The Ohio State University Wexner Medical Center

The presentation will be made available on the Glycobiology Education section of Palleon Pharmaceuticals’ website.

About Palleon Pharmaceuticals
Palleon Pharmaceuticals is a clinical-stage biotechnology company pioneering glycan editing, a new approach to immune modulation in autoimmune disease and cancer. Co-founded on the glycobiology research of Carolyn Bertozzi (2022 Nobel Laureate in Chemistry), Palleon’s pipeline includes E-602 (Phase 2, membranous nephropathy) and E-688/HLX316 (Phase 1, advanced solid tumors). www.palleonpharma.com

Contacts

Media
Lauren Crociati
Ten Bridge Communications
lcrociati@tenbridgecommunications.com

Industry:

Palleon Pharmaceuticals

Release Versions
English

Contacts

Media
Lauren Crociati
Ten Bridge Communications
lcrociati@tenbridgecommunications.com

More News From Palleon Pharmaceuticals

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of E-688/HLX316, a First-in-Class B7-H3-Targeted Sialidase for Advanced Solid Tumors

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, the first company to translate glycan editing science into clinical-stage therapeutics for immune modulation, today announced the first patient has been dosed in a Phase 1 clinical trial of E-688/HLX316, a first-in-class B7-H3-targeted sialidase. The study is being conducted in China by strategic collaborator Shanghai Henlius Biotech in patients with tumors prone to B7-H3 overexpression and hypersialylation, with an initial focus on plat...

Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals today presented preclinical data and announced the initiation of a human clinical trial for E-688/HLX316, a first-in-class B7-H3 targeted sialidase, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting “New Drugs on the Horizon” session. The presentation, titled “E-688/HLX316: A First-in-Class B7-H3 Targeted Sialidase for Boosting Innate and Adaptive Anti-Tumor Immunity” introduces the first ever t...

Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company developing engineered enzyme therapies that remove excessive sialic acid to treat autoimmune diseases and cancer, today announced upcoming presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego from April 17 – 22. Palleon will make an oral presentation during the “New Drugs on the Horizon” series on Sunday, April 19 and will present a poster on Wednesday, April 22. De...
Back to Newsroom